StockNews.AI
UTHR
StockNews.AI
174 days

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

1. UTHR achieved record revenues of $2.88 billion in 2024, a 24% increase. 2. This marks UTHR's third consecutive year of record revenue growth.

Earnings
-9.15%Current Return
VS
-0.04%S&P 500
$357.502/26 06:42 AM EDTEvent Start
$324.78502/27 01:45 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

The strong revenue growth aligns with positive investor sentiment and proven performance. Historically, similar achievements have led to increased stock valuations for companies in the healthcare sector.

How important is it?

The article outlines significant earnings growth, which usually influences stock performance and attracts investor interest. The clarity in financial performance could rally investor confidence further.

Why Long Term?

Sustained revenue growth over three years suggests long-term stability and potential market share expansion, leading to a positive outlook for UTHR.

Related Companies

VRTXAMGNBIIB
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. “I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue,” said Martine Rothblatt, P.

Related News